Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

• Status: Completed
• Trial end date: 2019-10-21
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the maximum tolerated dose of the combination of vorinostat, cisplatin, pemetrexed, and radiation therapy in patients with unresectable stage IIIA/IIIB non-small cell lung cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fox Chase Cancer Center
• Collaborator: National Comprehensive Cancer Network
• Treatments: Vorinostat

Criteria

Inclusion Criteria:

• biopsy proven non-squamous NSCLC with unresectable stage IIIA or dry IIIB disease.

• FEV1 >/= 1 liter

• ECOG PS 0 or 1

• Able to swallow and absorb enterally

• Measurable disease per RECIST 1.1

• Adequate organ and marrow function including calculated creatinine clearance >/= 60 mL/min hepatic enzymes and alk phos Exclusion Criteria:

• Chemotherapy or radiotherapynitrosureas)

• Active bleeding

• Known brain mets

• Prior thoracic radiotherapy that would lead to overlap with current radiation field.

• More than 10% weight loss in 6 months.

• Pancoast tumors, supraclavicular or contralateral hilar lymph node involvement

• Known HIV positive

• Prior treatment with an HDAC inhibitor